Effects of ß2-adrenergic receptor Gly16Arg genotype on guanosine (Gs) protein functionality in 3 genotypically defined patient subgroups with fibromyalgia syndrome. Gs protein functionality was defined in 2 ways: (1) as the intracellular cyclic adenosine monophosphate (cAMP) second message with the maximally effective stimulation dosage of isoproterenol, (2) and as the absolute increase of the intracellular cAMP second message achieved with the same dosage of isoproterenol. Values are mean ± SD compared by Student’s unpaired t test.
| Genotypes | p for Comparison | |||||
|---|---|---|---|---|---|---|
| Gly16Gly, n = 36 | Arg16Arg, n = 17 | Gly16Arg, n = 44 | Gly16Gly vs Arg16Arg | Gly16Gly vs Gly16Arg | Arg16Arg vs Gly16Arg | |
| Basal* | 5115 ± 3318 | 3160 ± 1605 | 4738 ± 3717 | 0.0056 | 0.63 | 0.024 |
| Gs functionality*† | ||||||
| Stimulated | 17541 ± 4840 | 12790 ± 3904 | 15602 ± 4761 | 0.00048 | 0.077 | 0.024 |
| Absolute increase | 12426 ± 4165 | 9630 ± 3061 | 10864 ± 3732 | 0.0087 | 0.085 | 0.19 |
↵* Basal intracellular cAMP second message in fmol/106 PBMC before stimulation with isoproterenol.
↵† Stimulated: intracellular cAMP second message concentration in fmol/106 PBMC achieved with maximal isoproterenol dosage. Absolute increase: difference betwen basal and stimulated intracellular cAMP concentrations in fmol/106 PBMC. PBMC: peripheral blood mononuclear cells.